January industry news: donanemab slows clinical decline of Alzheimer’s disease in Phase II trial

In this month’s industry news round-up: donanemab has showed significant slowing of decline in a composite measure of cognition and daily function in patients with early Alzheimer’s, troriluzole has not met the co-primary endpoints of a Phase II/III trial in patients with mild-to-moderate Alzheimer’s disease, NICE has rejected ozanimod as a treatment for relapsing–remitting multiple sclerosis in England and Wales, the European Commission has approved a new intramuscular route of administration for PLEGRIDY® for relapsing–remitting multiple sclerosis, and a new study from CERENOVUS demonstrates cost saving associated with First-Pass Effect in mechanical thrombectomy for treating acute ischemic stroke. Take a...